A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
| Status: | Active, not recruiting |
|---|---|
| Conditions: | HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | September 2014 |
| End Date: | December 2015 |
Raltegravir is the first marketed strand-transfer inhibitor of HIV-1 that was FDA approved
in 2007. It is currently one of the preferred treatment regimens for HIV by the Department
of Health and Human Services. It has become a widely used antiretroviral therapy option for
HIV infected patients. It provides good tolerability and a favorable lipid profile for
patients when compared to some other antiretroviral treatment options. Little data is
reported about efficacy in a minority patient population. Moreover, data in an indigent
minority population in the United States has not been aggregated before. Therefore this
study will investigate the efficacy of raltegravir in minority women residing in Houston, TX
who are HIV infected.
in 2007. It is currently one of the preferred treatment regimens for HIV by the Department
of Health and Human Services. It has become a widely used antiretroviral therapy option for
HIV infected patients. It provides good tolerability and a favorable lipid profile for
patients when compared to some other antiretroviral treatment options. Little data is
reported about efficacy in a minority patient population. Moreover, data in an indigent
minority population in the United States has not been aggregated before. Therefore this
study will investigate the efficacy of raltegravir in minority women residing in Houston, TX
who are HIV infected.
Inclusion Criteria:
1. HIV-infected women who picked up raltegravir in the year 2013 at Thomas Street Health
Center.
2. Minority women -Black/African American, Hispanic/Latino
Exclusion Criteria:
We found this trial at
1
site
Click here to add this to my saved trials
